Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors
https://doi.org/10.33667/2078-5631-2019-2-17(392)-19-22
Abstract
We present the comparative study of plasma chromogranin A (CgA) levels measured in 232 patients with different types of neuroendocrine tumors (NETs) and 66 healthy individuals using enzyme immunoassay Chromogranin A ELISA kit (Dako). CgA levels were significantly higher in patients with all types of NETs than in healthy subjects. CgA secretion were highly variable. The study demonstrate high diagnostic sensitivity of CgA, which was 80.6 % in overall group of NETs with specificity 98.5 %. We confirmed the prognostic significance of CgA, in this case the high basal levels of CgA (above 100 U/l) were significantly associated with less favorable prognosis of progression free survival after different types of treatment. The data confirms high efficiency of CgA as biomarker, which measurement enhances the accuracy of diagnosis and prognosis of NETs.
About the Authors
N. V. Lyubimova
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
Yu. S. Timofeev
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
T. K. Churikova
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
A. E. Kuzminov
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
N. E. Kushlinsky
National Medical Research Centre of Oncology n. a. N. N. Blokhin
Russian Federation
Russian Federation
Moscow
References
1. Ardill J. E. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann. Clin. Biochem. 2008. 45 (6). 539–559.
2. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer. 2011. 18 (1). 17–25.
3. Modlin I. M., Gustafsson B. I., Moss S. F., Pavel M., Tsolakis A. V., Kidd M. Chromogranin A — biological function and clinical utility in neuroendocrine tumor disease. Ann. Surg. Oncol. 2010. 17 (9). 2427–2443.
4. Aluri V., Dilon J. S. Biochemical testing in neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 2017. 46 (3). 669–677.
5. Vinik A. I., Silva M. P., Woltering E. A., Go V. L., Warner R., Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009. 38 (8). 876–889.
6. Louthan O. ChromograninA in physiology and oncology. Folia Biol. 2011. 57 (5). 173–181.
7. Nikou G. C., Marinou K., Thomakos P., Papageorgiou D., Sanzanidis V., Nikolaou P., Kosmidis C., Moulakakis A., Mallas E. Chromogranin A levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology. 2008. 8 (4–5). 510–519.
8. Jun E., Kim S. C., Song K. B., Hwang D. W., Lee J. H., Shin S. H., Hong S. M., Park K. M., Lee Y. J. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Surgery. 2017. 162 (1). 120–130.
9. Любимова Н. В., Чурикова Т. К., Кушлинский Н. Е. Хромогранин А — биохимический маркер нейроэндокринных опухолей. Бюллетень экспериментальной биологии и медицины. 2015. 160 (1). 657–660.
10. Любимова Н. В., Кушлинский Н. Е., Томс М. Г., Чурикова Т. К., Харитиди Т. Ю. Диагностическое значение биохимических маркеров нейроэндокринных опухолей. Клиническая лабораторная диагностика. 2016. 61 (7). 397–400.
11. Yao J. C., Pavel M., Phan A.T, Kulke M. H., Hoosen S., St Peter J., Cherfi A., Oberk K. E. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J. Clin. Endocrinol. Metab. 2011. 96 (12). 3741–3749.
12. Han X., Zhang C., Tang M., Xu X., Liu L., Ji Y., Pan B., Lou W. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur. J. Gastroenterol. Hepatol. 2015. 27 (5). 527–535.
13. Welin S., Stridsberg M., Cunningham J., Granberg D., Skogseid B., Oberg K., Eriksson B., Janson E. T. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology. 2009. 89 (3). 302–307.
14. Massironi S., Rossi R. E., Casazza G., Conte D., Ciafardini C., Galeazzi M., Peracchi M. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014. 100 (2–3). 240–249.
15. Arnold R., Wilke A., Rinke A., Mayer C., Kann P. H., Klose K. J., Scherag A., Hahmann M., Müller H. H., Barth P. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin. Gastroenterol. Hepatol. 2008. 6 (7). 820–827.
Review
For citations:
Lyubimova N.V., Timofeev Yu.S., Churikova T.K., Kuzminov A.E., Kushlinsky N.E. Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors. Medical alphabet. 2019;2(17):19-22. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-17(392)-19-22
Views:
722
Email this article 